Shares of Vistagen Therapeutics, Inc. (NASDAQ:VTGN - Get Free Report) crossed below its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $2.79 and traded as low as $2.60. Vistagen Therapeutics shares last traded at $2.70, with a volume of 118,758 shares traded.
Vistagen Therapeutics Stock Performance
The company has a market cap of $82.68 million, a PE ratio of -2.40 and a beta of 0.77. The stock has a 50 day moving average of $2.81 and a 200-day moving average of $2.99.
Vistagen Therapeutics (NASDAQ:VTGN - Get Free Report) last released its quarterly earnings data on Thursday, February 13th. The company reported ($0.46) earnings per share for the quarter, beating analysts' consensus estimates of ($0.48) by $0.02. The business had revenue of $230 billion during the quarter, compared to analyst estimates of $0.18 million. Vistagen Therapeutics had a negative return on equity of 36.35% and a negative net margin of 4,521.71%. Equities research analysts forecast that Vistagen Therapeutics, Inc. will post -1.85 EPS for the current year.
Hedge Funds Weigh In On Vistagen Therapeutics
Institutional investors have recently modified their holdings of the stock. R Squared Ltd purchased a new position in shares of Vistagen Therapeutics during the 4th quarter valued at about $25,000. Jane Street Group LLC purchased a new position in shares of Vistagen Therapeutics in the 3rd quarter valued at about $59,000. Virtu Financial LLC increased its stake in shares of Vistagen Therapeutics by 30.5% in the 3rd quarter. Virtu Financial LLC now owns 20,210 shares of the company's stock valued at $61,000 after purchasing an additional 4,722 shares in the last quarter. HighTower Advisors LLC purchased a new position in shares of Vistagen Therapeutics in the 3rd quarter valued at about $64,000. Finally, Boothbay Fund Management LLC purchased a new position in shares of Vistagen Therapeutics in the 4th quarter valued at about $66,000. Hedge funds and other institutional investors own 78.39% of the company's stock.
Vistagen Therapeutics Company Profile
(
Get Free Report)
Vistagen Therapeutics, Inc, a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.
Read More
Before you consider Vistagen Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vistagen Therapeutics wasn't on the list.
While Vistagen Therapeutics currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
